Dyne Therapeutics announced the pricing of an upsized public offering of 18.3 million common shares at $20.50 each, raising approximately $375 million before expenses. The offering is expected to close around July 23, 2026, with underwriters having a 30-day option to buy additional shares. Proceeds will support Dyne's clinical programs targeting neuromuscular diseases like Duchenne muscular dystrophy. This capital raise aims to advance their therapeutic developments and clinical trials.
Diana Burgon of Berkshire Hathaway HomeServices Bayside Realty was named to the 2025 Honor Society, recognizing the top 17% of sales professionals in the network. This award highlights her outstanding sales performance and dedication to clients. Sinc...
Lido DAO (LDO) surged 13% in 24 hours, reaching a two-month high of $0.40 supported by a strong $0.35 base. The rally coincided with a unanimous governance vote approving protocol upgrades, boosting market interest. Trading volume and open interest r...
Bilibili is expected to report strong Q2 earnings driven by a loyal user base and significant membership growth. Revenue growth is anticipated from value-added services and advertising, especially with the introduction of the Pause Ads feature, which...
A new study found that adults with alcohol use disorder (AUD) who started treatment with GLP-1 receptor agonists like semaglutide and tirzepatide had significantly fewer alcohol-related hospitalizations compared to those on other diabetes or obesity ...
Spire Inc, a Missouri-based natural gas utility, is rated a Strong Buy after refocusing on its core natural gas distribution business by trading volatile midstream and storage assets for more stable local distribution assets. This move improves earni...
